By: Delegates Bromwell, Benson, Costa, DeBoy, Elliott, Kipke, Krebs, Kullen, McDonough, Morhaim, Reznik, Rudolph, Schuler, Shewell, Stocksdale, and Weldon Weldon, Beitzel, Donoghue, Hammen, Kach, Nathan-Pulliam, Oaks, Pena-Melnyk, Pendergrass, Riley, and V. Turner Introduced and read first time: January 17, 2008 Assigned to: Health and Government Operations Committee Report: Favorable with amendments

House action: Adopted Read second time: March 18, 2008

CHAPTER _____

1 AN ACT concerning

 $\mathbf{2}$

Pharmacy Benefits Managers – Transparency <u>Disclosures</u>

3 FOR the purpose of requiring a pharmacy benefits manager to disclose in writing 4 certain information to a prospective purchaser and a purchaser; specifying the 5 manner in which certain disclosures must be provided; providing that a 6 pharmacy benefits manager need not make certain disclosures unless and until 7 the prospective purchaser or the purchaser agrees in writing to maintain 8 certain information as confidential; providing that certain agreements may 9 include certain remedies and certain persons; requiring a contract executed by a pharmacy benefits manager for the provision of pharmacy benefits management 10 11 services to include certain items; requiring the Commissioner to adopt certain 12 regulations on or before a certain date; requiring certain pharmacy benefits managers to provide certain information and offer to provide a certain report to 13 a certain purchaser before entering into a contract with the purchaser under 14 certain circumstances; requiring a pharmacy benefits manager to provide 15certain reports to a certain purchaser under certain circumstances; providing 16 that this Act does not diminish the authority of the Office of the Attorney 17 18 General or the Maryland Insurance Commissioner to obtain and use certain 19 information in certain proceedings; authorizing the Commissioner to assess a 20certain penalty or require certain restitution under certain circumstances; making certain provisions of law applicable to health maintenance 21

EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW.

[Brackets] indicate matter deleted from existing law.

Underlining indicates amendments to bill.

Strike out indicates matter stricken from the bill by amendment or deleted from the law by amendment.



J3

organizations; defining certain terms; and generally relating to regulation of

2	pharmacy benefits managers.
3	BY adding to
4	Article – Insurance
5	Section 15–1601 through 15–1609 15–1606 to be under the new subtitle
6	"Subtitle 16. Pharmacy Benefits Managers"
$\overline{7}$	Annotated Code of Maryland
8	(2006 Replacement Volume and 2007 Supplement)
9	BY adding to
10	Article – Health – General
11	Section 19–706(ppp)
12	Annotated Code of Maryland
13	(2005 Replacement Volume and 2007 Supplement)
14	SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF
15	MARYLAND, That the Laws of Maryland read as follows:
16	Article – Insurance
10	Article – Insurance
17	SUBTITLE 16. PHARMACY BENEFITS MANAGERS.
10	
18	15–1601.
19	(A) IN THIS SUBTITLE THE FOLLOWING WORDS HAVE THE MEANINGS
20	INDICATED.
20	
21	(b) " Beneficiary" means an individual on whose behalf a
22	PURCHASER ENTERS INTO AN AGREEMENT WITH A PHARMACY BENEFITS
23	MANAGER.
20	
24	(C) "LABELER" MEANS A PERSON THAT:
25	(1) RECEIVES PRESCRIPTION DRUGS FROM A MANUFACTURER OR
26	WHOLESALER AND REPACKAGES THOSE DRUGS FOR LATER RETAIL SALE; AND
27	(2) HAS A LABELER CODE FROM THE U.S. FOOD AND DRUG
28	ADMINISTRATION UNDER 21 CFR § 207.20.
29	(d) (1) "Pharmacy benefits management services" means the
30	ADMINISTRATION OR MANAGEMENT OF PRESCRIPTION DRUG BENEFITS.
31	(2) "PHARMACY BENEFITS MANAGEMENT SERVICES" INCLUDES:

 $\mathbf{2}$

1

1	(I) PROCUREMENT OF PRESCRIPTION DRUGS AT A
2	NEGOTIATED RATE FOR DISPENSATION WITHIN THE STATE;
3	(II) PROCESSING OF PRESCRIPTION DRUG CLAIMS;
4	(III) ADMINISTRATION OF PAYMENTS RELATED TO
5	PRESCRIPTION DRUG CLAIMS; AND
6	(IV) NEGOTIATING OR ENTERING INTO CONTRACTUAL
7	ARRANGEMENTS WITH PHARMACY PROVIDERS.
8	(e) " Pharmacy benefits manager" means a person that
9	PERFORMS PHARMACY BENEFITS MANAGEMENT SERVICES.
10	(F) "PROSPECTIVE PURCHASER" MEANS A PERSON TO WHICH A
11	PHARMACY BENEFITS MANAGER OFFERS TO PROVIDE PHARMACY BENEFITS
12	MANAGEMENT SERVICES.
13	(G) (1) "Purchaser" means a person that enters into an
14	AGREEMENT WITH A PHARMACY BENEFITS MANAGER FOR THE PROVISION OF
15	PHARMACY BENEFITS MANAGEMENT SERVICES.
16	(2) "Purchaser" includes the State.
17	(H) "Trade secret" has the meaning stated in § 11–1201 of the
18	Commercial Law Article.
19	15–1602.
20	(A) THE PROVISIONS OF THIS SUBTITLE DO NOT APPLY TO A MANAGED
21	CARE ORGANIZATION AUTHORIZED BY TITLE 15, SUBTITLE 1 OF THE HEALTH -
22	General Article.
23	(B) THE PROVISIONS OF THIS SUBTITLE DO NOT APPLY TO AN INSURER.
$\frac{23}{24}$	(B) THE PROVISIONS OF THIS SUBTITLE DO NOT APPLY TO AN INSURER, NONPROFIT HEALTH SERVICE PLAN, OR HEALTH MAINTENANCE ORGANIZATION,
$\frac{21}{25}$	OR AN AFFILIATE, SUBSIDIARY, OR OTHER RELATED ENTITY OF AN INSURER,
26	NONPROFIT HEALTH SERVICE PLAN, OR HEALTH MAINTENANCE ORGANIZATION
27	ACTING OR REPRESENTING ITSELF AS A PHARMACY BENEFITS MANAGER IF;
28	(1) THE INSURER, NONPROFIT HEALTH SERVICE PLAN, OR
20 29	(1) THE INSURER, NONPROFIT HEALTH SERVICE PLAN, OR HEALTH MAINTENANCE ORGANIZATION OR THE AFFILIATE, SUBSIDIARY, OR
30	OTHER RELATED ENTITY OF THE INSURER, NONPROFIT HEALTH SERVICE PLAN,
31	OR HEALTH MAINTENANCE ORGANIZATION DIRECTLY OFFERS OR PROVIDES
32	PHARMACY BENEFITS MANAGEMENT SERVICES; AND

1(2)THE PHARMACY BENEFITS MANAGEMENT SERVICES ARE2OFFERED OR PROVIDED ONLY TO ENROLLEES, SUBSCRIBERS, OR INSUREDS3WHO ALSO ARE COVERED BY HEALTH BENEFITS OFFERED OR PROVIDED BY THE4INSURER, NONPROFIT HEALTH SERVICE PLAN, OR HEALTH MAINTENANCE5ORGANIZATION.

6 15-1603.

7 (A) A PHARMACY BENEFITS MANAGER SHALL DISCLOSE TO A 8 PROSPECTIVE PURCHASER IN WRITING:

9 (1) THE AMOUNT OF ALL REBATES, ADMINISTRATIVE FEES, 10 DETAILING PAYMENTS, EDUCATIONAL PAYMENTS, AND OTHER RETROSPECTIVE 11 DISCOUNTS THAT THE PHARMACY BENEFITS MANAGER ESTIMATES IT WOULD 12 RECEIVE, DIRECTLY OR INDIRECTLY, FROM PHARMACEUTICAL 13 MANUFACTURERS OR LABELERS IN CONNECTION WITH PRESCRIPTION DRUG 14 BENEFITS SPECIFIC TO THE PROSPECTIVE PURCHASER, IF THE PROSPECTIVE 15 PURCHASER WERE TO CONTRACT WITH THE PHARMACY BENEFITS MANAGER;

16 (2) THE NATURE, TYPE, AND AMOUNT OF ALL OTHER REVENUE
 THAT THE PHARMACY BENEFITS MANAGER ESTIMATES IT WOULD RECEIVE,
 DIRECTLY OR INDIRECTLY, FROM PHARMACEUTICAL MANUFACTURERS OR
 LABELERS IN CONNECTION WITH PRESCRIPTION DRUG BENEFITS SPECIFIC TO
 THE PROSPECTIVE PURCHASER, IF THE PROSPECTIVE PURCHASER WERE TO
 CONTRACT WITH THE PHARMACY BENEFITS MANAGER;

22(3)ANY ADMINISTRATIVE OR OTHER FEES THAT WOULD BE23CHARGED BY THE PHARMACY BENEFITS MANAGER TO THE PROSPECTIVE24PURCHASER;

25 (4) ANY ARRANGEMENTS WITH PRESCRIBING PROVIDERS,
 26 MEDICAL GROUPS, INDIVIDUAL PRACTICE ASSOCIATIONS, PHARMACY
 27 PROVIDERS, OR OTHER PERSONS THAT ARE ASSOCIATED WITH ACTIVITIES OF
 28 THE PHARMACY BENEFITS MANAGER TO ENCOURAGE FORMULARY COMPLIANCE
 29 OR OTHERWISE MANAGE PRESCRIPTION DRUG BENEFITS; AND

30 (5) A LIST OF ANY DRUGS THAT THE PHARMACY BENEFITS
 31 MANAGER, DIRECTLY OR INDIRECTLY, REPACKAGED AND ASSIGNED NEW OR
 32 DIFFERENT NATIONAL DRUG CODE NUMBERS INCLUDING, FOR EACH DRUG ON
 33 THE LIST;

- 34
- (I) THE DRUG NAME AND STRENGTH;

 35
 (II)
 THE ORIGINAL NATIONAL DRUG CODE NUMBER AND

 36
 THE NEW NATIONAL DRUG CODE NUMBER; AND

1	(III) THE ORIGINAL PRICE AND THE NEW PRICE.
2	(B) THE DISCLOSURE REQUIRED UNDER SUBSECTION (A)(1) OF THIS
3	SECTION SHALL BE PROVIDED:
4	
4	(1) IN THE AGGREGATE;
5	(2) FOR EACH THERAPEUTIC CLASS OF DRUGS ON A LIST OF
6	SPECIFIED THERAPEUTIC CLASSES; AND
7	(3) for five individual prescribed drugs in each
8	THERAPEUTIC CLASS OF DRUGS AS REQUESTED BY THE PURCHASER.
9	(C) A THERAPEUTIC CLASS SHALL INCLUDE AT LEAST TWO DRUGS.
10	15-1604.
10	
11	(A) AT LEAST QUARTERLY, A PHARMACY BENEFITS MANAGER SHALL
12	DISCLOSE TO A PURCHASER IN WRITING:
13	(1) THE AMOUNT OF ALL REBATES, ADMINISTRATIVE FEES,
14	DETAILING PAYMENTS, EDUCATIONAL PAYMENTS, AND OTHER RETROSPECTIVE
15	DISCOUNTS THAT THE PHARMACY BENEFITS MANAGER RECEIVES, DIRECTLY OR
16	INDIRECTLY, FROM PHARMACEUTICAL MANUFACTURERS OR LABELERS IN
17	CONNECTION WITH PRESCRIPTION DRUG BENEFITS SPECIFIC TO THE
18	PURCHASER;
19	(2) THE NATURE, TYPE, AND AMOUNT OF ALL OTHER REVENUE
20	THAT THE PHARMACY BENEFITS MANAGER RECEIVES. DIRECTLY OR
21	INDIRECTLY, FROM PHARMACEUTICAL MANUFACTURERS OR LABELERS IN
22	CONNECTION WITH PRESCRIPTION DRUG BENEFITS SPECIFIC TO THE
23	PURCHASER;
24	(3) ANY PRESCRIPTION DRUG UTILIZATION INFORMATION
25	RELATED TO UTILIZATION BY THE PURCHASER'S BENEFICIARIES OR
26	AGGREGATE UTILIZATION DATA THAT IS NOT SPECIFIC TO AN INDIVIDUAL
27	BENEFICIARY, PRESCRIBER, OR PURCHASER;
. -	
28	(4) ANY ADMINISTRATIVE OR OTHER FEES CHARGED BY THE
29	PHARMACY BENEFITS MANAGER TO THE PURCHASER;
30	(5) ANY ARRANGEMENTS WITH PRESCRIBING PROVIDERS,
31	MEDICAL GROUPS, INDIVIDUAL PRACTICE ASSOCIATIONS, PHARMACY

32 PROVIDERS, OR OTHER PERSONS THAT ARE ASSOCIATED WITH ACTIVITIES OF

	6 HOUSE BILL 120
1	THE PHARMACY BENEFITS MANAGER TO ENCOURAGE FORMULARY COMPLIANCE
2	OR OTHERWISE MANAGE PRESCRIPTION DRUG BENEFITS;
3	(6) A LIST OF ANY DRUGS THAT THE PHARMACY BENEFITS
4	MANAGER, DIRECTLY OR INDIRECTLY, REPACKAGED AND ASSIGNED NEW OR
5	DIFFERENT NATIONAL DRUG CODE NUMBERS INCLUDING, FOR EACH DRUG ON
6	THE LIST:
7	(I) THE DRUG NAME AND STRENGTH;
8	(II) THE ORIGINAL NATIONAL DRUG CODE NUMBER AND
9	THE NEW NATIONAL DRUG CODE NUMBER; AND
10	(III) THE ORIGINAL PRICE AND THE NEW PRICE; AND
11	(7) A LIST OF PRESCRIPTIONS FOR WHICH THERE WAS A
12	DIFFERENCE BETWEEN THE PRICE PAID TO A RETAIL PHARMACY AND THE
13	AMOUNT THAT WAS BILLED TO THE PURCHASER INCLUDING, FOR EACH
14	PRESCRIPTION:
15	(I) THE PRESCRIPTION NUMBER;
16	(II) THE DATE THE PRESCRIPTION WAS PROCESSED BY THE
17	PHARMACY BENEFITS MANAGER;
18	(III) THE NATIONAL DRUG CODE NUMBER;
19	(IV) THE BENEFICIARY'S NAME; AND
$\begin{array}{c} 20\\ 21 \end{array}$	(V) THE PRICE PAID TO THE RETAIL PHARMACY AND THE AMOUNT BILLED TO THE PURCHASER.
22	(B) THE DISCLOSURE REQUIRED UNDER SUBSECTION (A)(1) OF THIS
23	SECTION SHALL BE PROVIDED:
24	(1) IN THE AGGREGATE;
25	(2) FOR EACH THERAPEUTIC CLASS OF DRUGS ON A LIST OF
$\frac{25}{26}$	SPECIFIED THERAPEUTIC CLASSES; AND
27	(3) FOR FIVE INDIVIDUAL PRESCRIBED DRUGS IN EACH
28	THERAPEUTIC CLASS OF DRUGS AS REQUESTED BY THE PURCHASER.
29	(C) A THERAPEUTIC CLASS SHALL INCLUDE AT LEAST TWO DRUGS.

1 15-1605.

2 (A) EXCEPT FOR UTILIZATION INFORMATION, AND EXCEPT AS 3 PROVIDED IN SUBSECTION (D) OF THIS SECTION, A PHARMACY BENEFITS 4 MANAGER NEED NOT MAKE THE DISCLOSURES REQUIRED UNDER §§ 15–1603 5 AND 15–1604 OF THIS SUBTITLE UNLESS AND UNTIL THE PROSPECTIVE 6 PURCHASER OR THE PURCHASER AGREES IN WRITING TO MAINTAIN AS 7 CONFIDENTIAL ANY PROPRIETARY INFORMATION DISCLOSED BY THE 8 PHARMACY BENEFITS MANAGER.

- 9 (B) THE AGREEMENT UNDER SUBSECTION (A) OF THIS SECTION MAY:
- 10(1)PROVIDE FOR EQUITABLE AND LEGAL REMEDIES IN THE11EVENT OF A VIOLATION OF THE ACREEMENT; AND
- 12(2)INCLUDE PERSONS WITH WHICH THE PROSPECTIVE13PURCHASER OR PURCHASER CONTRACTS TO PROVIDE CONSULTING SERVICES14RELATING TO PHARMACY BENEFITS MANAGEMENT SERVICES.
- 15 (C) **PROPRIETARY INFORMATION INCLUDES:**
- 16 (1) TRADE SECRETS; AND

17 (2) INFORMATION ABOUT PRICING, COSTS, REVENUES, TAXES,
 18 MARKET SHARE, NEGOTIATING STRATEGIES, CUSTOMERS, AND PERSONNEL
 19 HELD BY A PHARMACY BENEFITS MANAGER AND USED FOR ITS BUSINESS
 20 PURPOSES.

- 21 (D) THIS SECTION DOES NOT DIMINISH THE AUTHORITY OF THE OFFICE
 22 OF THE ATTORNEY GENERAL OR THE COMMISSIONER TO OBTAIN INFORMATION
 23 AND USE THE INFORMATION IN ANY PROCEEDING.
- 24 15-1606.

25A CONTRACT EXECUTED BY A PHARMACY BENEFITS MANAGER FOR THE26PROVISION OF PHARMACY BENEFITS MANAGEMENT SERVICES SHALL INCLUDE:

- 27 (1) THE AMOUNT OF THE TOTAL REVENUES, REBATES, AND
 28 DISCOUNTS IDENTIFIED IN §§ 15–1603 AND 15–1604 OF THIS SUBTITLE THAT
 29 WILL BE PASSED ON TO THE PURCHASER;
- 30 (2) THE MAXIMUM ALLOWABLE COST AND AVERAGE WHOLESALE
 31 PRICE RESOURCES USED TO DETERMINE THE PRICE PAID TO A PHARMACY AND
 32 BILLED TO THE PURCHASER;

	8		HOUSE BILL 120
$egin{array}{c} 1 \\ 2 \\ 3 \end{array}$		SCLOS	CONDITIONS UNDER WHICH BENEFICIARY UTILIZATION ED OR SOLD BY THE PHARMACY BENEFITS MANAGER TO AN THE PURCHASER;
4	(4)	ANY A	ADMINISTRATIVE OR OTHER FEES:
5 6	THE PURCHASER	(I) ; OR	CHARGED BY THE PHARMACY BENEFITS MANAGER TO
7 8	BEHALF OF THE	(II) PURCH	COLLECTED BY THE PHARMACY BENEFITS MANAGER ON ASER;
9 10 11	(5) CONDUCTED OF SERVICES;	(I) THE	THE CONDITIONS UNDER WHICH AN AUDIT WILL BE CONTRACT FOR PHARMACY BENEFITS MANAGEMENT
12		(II)	WHO WILL CONDUCT THE AUDIT; AND
13		(III)	WHO WILL PAY FOR THE AUDIT;
14 15 16 17 18	PERSONS OTHER	NDIRE(1- THAI FIC-TC	REVENUES, REBATES, OR DISCOUNTS RECEIVED, CTLY, BY THE PHARMACY BENEFITS MANAGER FROM N PHARMACEUTICAL MANUFACTURERS AND LABELERS THE PHARMACY BENEFITS MANAGEMENT SERVICES TO URCHASER;
19 20 21	(7) NOTIFICATION O THE PURCHASER	F CHA	PROCESS FOR THE DEVELOPMENT OF FORMULARIES, NGES TO FORMULARIES, AND APPROVAL OF CHANGES BY
22	(8)		GREEMENT TO PROVIDE TO THE PURCHASER A LIST OF
$\begin{array}{c} 23 \\ 24 \end{array}$			THERE WAS A DIFFERENCE BETWEEN THE PRICE
$\frac{24}{25}$			RMACY AND THE AMOUNT THAT WILL BE OR WAS BILLED CLUDING, FOR EACH PRESCRIPTION:
26		(I)	THE PRESCRIPTION NUMBER;
27		(II)	THE DATE THE PRESCRIPTION DRUG WAS PROCESSED
28	BY THE PHARMA	CY BEN	EFITS MANAGER;
29		(III)	THE NATIONAL DRUG CODE NUMBER;
30		(IV)	THE BENEFICIARY'S NAME; AND

 1
 (v)
 THE PRICE PAID TO THE RETAIL PHARMACY AND THE

 2
 AMOUNT BILLED TO THE PURCHASER.

3 15-1607.

ALL DISCLOSURES MADE UNDER THIS SUBTITLE SHALL COMPLY WITH
 THE PRIVACY STANDARDS OF THE FEDERAL HEALTH INSURANCE PORTABILITY
 AND ACCOUNTABILITY ACT.

- 7 15–1608.
- 8 On or before April 1, 2009, the Commissioner shall adopt 9 Regulations to implement this subtitle.
- 10 **<u>15-1609.</u>**
- 11 **<u>15–1601.</u>**

12(A)IN THIS SUBTITLE THE FOLLOWING WORDS HAVE THE MEANINGS13INDICATED.

14(B)"BENEFICIARY"MEANSANINDIVIDUALWHORECEIVES15PRESCRIPTION DRUG COVERAGE OR BENEFITS FROM A PURCHASER.

16 (C) <u>"ERISA" HAS THE MEANING STATED IN § 8–301 OF THIS ARTICLE.</u>

17 (D) (1) "MANUFACTURER PAYMENTS" MEANS ANY COMPENSATION
 18 OR REMUNERATION A PHARMACY BENEFITS MANAGER RECEIVES FROM OR ON
 19 BEHALF OF A PHARMACEUTICAL MANUFACTURER.

20 (2) "MANUFACTURER PAYMENTS" INCLUDES:

21(I)PAYMENTSRECEIVEDINACCORDANCEWITH22AGREEMENTSWITHPHARMACEUTICALMANUFACTURERSFORFORMULARY23PLACEMENT AND, IF APPLICABLE, DRUG UTILIZATION;

- 24 (II) <u>REBATES, REGARDLESS OF HOW CATEGORIZED;</u>
- 25 (III) MARKET SHARE INCENTIVES;
- 26 (IV) <u>COMMISSIONS</u>;
- 27 (V) <u>FEES UNDER PRODUCTS AND SERVICES AGREEMENTS;</u>

	10 HOUSE BILL 120
1 2	(VI) ANY FEES RECEIVED FOR THE SALE OF UTILIZATION DATA TO A PHARMACEUTICAL MANUFACTURER; AND
3	(VII) ADMINISTRATIVE OR MANAGEMENT FEES.
4	(3) "MANUFACTURER PAYMENTS" DOES NOT INCLUDE PURCHASE
5	DISCOUNTS BASED ON INVOICED PURCHASE TERMS.
6	(E) <u>"Nonprofit health maintenance organization" has the</u>
7	<u>Meaning stated in § 6–121(A) of this article.</u>
8	(F) (1) "PHARMACY BENEFITS MANAGEMENT SERVICES" MEANS:
9	(I) <u>THE PROCUREMENT OF PRESCRIPTION DRUGS AT A</u>
10	<u>NEGOTIATED RATE FOR DISPENSATION WITHIN THE STATE TO BENEFICIARIES;</u>
$11 \\ 12 \\ 13$	(II) <u>THE ADMINISTRATION OR MANAGEMENT OF</u> PRESCRIPTION DRUG COVERAGE PROVIDED BY A PURCHASER FOR BENEFICIARIES; AND
14	(III) ANY OF THE FOLLOWING SERVICES PROVIDED WITH
15	REGARD TO THE ADMINISTRATION OF PRESCRIPTION DRUG COVERAGE:
16	<u>1.</u> MAIL SERVICE PHARMACY;
17	2. <u>CLAIMS PROCESSING, RETAIL NETWORK</u>
18	MANAGEMENT, AND PAYMENT OF CLAIMS TO PHARMACIES FOR PRESCRIPTION
19	DRUGS DISPENSED TO BENEFICIARIES;
20	<u>3.</u> <u>CLINICAL FORMULARY DEVELOPMENT AND</u>
21	<u>MANAGEMENT SERVICES;</u>
22	4. <u>REBATE CONTRACTING AND ADMINISTRATION;</u>
23	5. <u>PATIENT COMPLIANCE, THERAPEUTIC</u>
24	INTERVENTION, AND GENERIC SUBSTITUTION PROGRAMS; OR
25	<u>6.</u> DISEASE MANAGEMENT PROGRAMS.
26	(2) <u>"PHARMACY BENEFITS MANAGEMENT SERVICES" DOES NOT</u>
27	INCLUDE ANY SERVICE PROVIDED BY A NONPROFIT HEALTH MAINTENANCE
28	ORGANIZATION THAT OPERATES AS A GROUP MODEL, PROVIDED THAT THE
29	SERVICE:

$rac{1}{2}$	(I) IS PROVIDED SOLELY TO A MEMBER OF THE NONPROFIT HEALTH MAINTENANCE ORGANIZATION; AND
3 4	(II) IS FURNISHED THROUGH THE INTERNAL PHARMACY OPERATIONS OF THE NONPROFIT HEALTH MAINTENANCE ORGANIZATION.
5 6	(G) <u>"Pharmacy benefits manager" means a person that</u> <u>performs pharmacy benefits management services.</u>
7	(H) "PROPRIETARY INFORMATION" MEANS:
8	(1) <u>A TRADE SECRET;</u>
9	(2) CONFIDENTIAL COMMERCIAL INFORMATION; OR
10	(3) <u>CONFIDENTIAL FINANCIAL INFORMATION.</u>
11	(I) (1) "PURCHASER" MEANS THE STATE EMPLOYEE AND RETIREE
$\frac{12}{13}$	HEALTH AND WELFARE BENEFITS PROGRAM, AN INSURER, A NONPROFIT HEALTH SERVICE PLAN, OR A HEALTH MAINTENANCE ORGANIZATION THAT:
10	IEALTH SERVICE I LAN, OR A HEALTH MAINTENANCE ORGANIZATION THAT.
14	(I) PROVIDES PRESCRIPTION DRUG COVERAGE OR
15	BENEFITS IN THE STATE; AND
16	(II) ENTERS INTO AN AGREEMENT WITH A PHARMACY
17	BENEFITS MANAGER FOR THE PROVISION OF PHARMACY BENEFITS
18	MANAGEMENT SERVICES.
10	
$\frac{19}{20}$	(2) <u>"PURCHASER" DOES NOT INCLUDE A PERSON THAT PROVIDES</u>
$\frac{20}{21}$	PRESCRIPTION DRUG COVERAGE OR BENEFITS THROUGH PLANS SUBJECT TO ERISA AND DOES NOT PROVIDE PRESCRIPTION DRUG COVERAGE OR BENEFITS
22	THROUGH INSURANCE, UNLESS THE PERSON IS A MULTIPLE EMPLOYER
$\frac{22}{23}$	WELFARE ARRANGEMENT AS DEFINED IN § 514(B)(6)(A)(II) OF ERISA.
24	(J) "REBATE SHARING CONTRACT" MEANS A CONTRACT BETWEEN A
25 26	PHARMACY BENEFITS MANAGER AND A PURCHASER UNDER WHICH THE
$\frac{26}{27}$	PHARMACY BENEFITS MANAGER AGREES TO SHARE MANUFACTURER PAYMENTS
41	WITH THE PURCHASER.
28	(K) "TRADE SECRET" HAS THE MEANING STATED IN § 11–1201 OF THE
28 29	(K) <u>"Trade secret" has the meaning stated in § 11-1201 of the</u> Commercial Law Article.

30 <u>15–1602.</u>

1	THE PROVISIONS OF §§ 15–1603 THROUGH 15–1606 OF THIS SUBTITLE DO
2	NOT APPLY TO A PHARMACY BENEFITS MANAGER WHEN PROVIDING PHARMACY
3	BENEFITS MANAGEMENT SERVICES TO A PURCHASER THAT IS AFFILIATED WITH
4	THE PHARMACY BENEFITS MANAGER THROUGH COMMON OWNERSHIP WITHIN
5	AN INSURANCE HOLDING COMPANY.
6	<u>15–1603.</u>
7	(A) BEFORE ENTERING INTO A CONTRACT WITH A PURCHASER, A
8	PHARMACY BENEFITS MANAGER:
9	(1) AS APPLICABLE, SHALL INFORM THE PURCHASER THAT THE
10	PHARMACY BENEFITS MANAGER MAY:
11	(I) SOLICIT AND RECEIVE MANUFACTURER PAYMENTS;
12	(II) PASS THROUGH OR RETAIN THE MANUFACTURER
13	PAYMENTS DEPENDING ON THE CONTRACT TERMS WITH A PURCHASER;
14	(III) SELL AGGREGATE UTILIZATION INFORMATION; AND
15	
15 16	(IV) SHARE AGGREGATE UTILIZATION INFORMATION WITH
10	OTHER ENTITIES; AND
17	(2) SHALL OFFER TO PROVIDE TO THE PURCHASER A REPORT
18	THAT CONTAINS THE:
10	<u>IIIAI CONTAINS IIIE.</u>
19	(I) NET REVENUE OF THE PHARMACY BENEFITS MANAGER
20	FROM SALES OF PRESCRIPTION DRUGS TO PURCHASERS MADE THROUGH THE
21	PHARMACY BENEFITS MANAGER'S NETWORK OF CONTRACTUALLY AFFILIATED
22	RETAIL PHARMACIES OR THROUGH THE PHARMACY BENEFITS MANAGER'S MAIL
23	ORDER PHARMACIES, WITH RESPECT TO THE PHARMACY BENEFITS MANAGER'S
24	ENTIRE CLIENT BASE OF PURCHASERS; AND
25	(II) AMOUNT OF ALL MANUFACTURER PAYMENTS EARNED
26	BY THE PHARMACY BENEFITS MANAGER.
27	(B) (1) IF A PURCHASER REQUESTS THE INFORMATION DESCRIBED
28	IN SUBSECTION (A)(2) OF THIS SECTION, A PHARMACY BENEFITS MANAGER
29	SHALL PROVIDE THE INFORMATION BEFORE ENTERING INTO A CONTRACT WITH
30	THE PURCHASER.
31	(9) NORWINIANDING THE PROVISIONS OF DADAGDADY (1) OF
$\frac{31}{32}$	(2) NOTWITHSTANDING THE PROVISIONS OF PARAGRAPH (1) OF THIS SUBSECTION IF A DHADMACY DENFEITS MANACED DECUIDES A
32 33	THIS SUBSECTION, IF A PHARMACY BENEFITS MANAGER REQUIRES A NONDISCLOSUBE ACREEMENT UNDER WHICH A DUDCHASER ACREES THAT THE
00	NONDISCLOSURE AGREEMENT UNDER WHICH A PURCHASER AGREES THAT THE

1	INFORMATION DESCRIBED IN SUBSECTION (A)(2) OF THIS SECTION IS
2	PROPRIETARY INFORMATION, THE PHARMACY BENEFITS MANAGER MAY NOT BE
3	REQUIRED TO PROVIDE THE INFORMATION UNTIL THE PURCHASER HAS SIGNED
4	THE NONDISCLOSURE AGREEMENT.
5	<u>15–1604.</u>
6	(A) IF A PURCHASER HAS A REBATE SHARING CONTRACT, A PHARMACY
7	BENEFITS MANAGER SHALL OFFER TO PROVIDE THE PURCHASER A REPORT FOR
8	EACH FISCAL QUARTER AND EACH FISCAL YEAR THAT CONTAINS THE AMOUNT
9	OF THE:
10	(1) NET REVENUE OF THE PHARMACY BENEFITS MANAGER FROM
11	SALES OF PRESCRIPTION DRUGS TO PURCHASERS MADE THROUGH THE
12	PHARMACY BENEFITS MANAGER'S NETWORK OF CONTRACTUALLY AFFILIATED
13	RETAIL PHARMACIES OR THROUGH THE PHARMACY BENEFITS MANAGER'S MAIL
14	ORDER PHARMACIES, WITH RESPECT TO THE PHARMACY BENEFITS MANAGER'S
15	ENTIRE CLIENT BASE OF PURCHASERS;
16	(2) TOTAL PRESCRIPTION DRUG EXPENDITURES APPLICABLE TO
17	THE PURCHASER;
18	(3) TOTAL MANUFACTURER PAYMENTS EARNED BY THE
19	PHARMACY BENEFITS MANAGER DURING THE APPLICABLE REPORTING PERIOD;
20	AND
21	(4) TOTAL REBATES APPLICABLE TO THE PURCHASER DURING
22	THE APPLICABLE REPORTING PERIOD.
23	(B) IF THE EXACT AMOUNT OF EACH ITEM TO BE REPORTED UNDER
24	SUBSECTION (A) OF THIS SECTION IS NOT KNOWN BY THE PHARMACY BENEFITS
25	MANAGER AT THE TIME OF ITS REPORT, THE PHARMACY BENEFITS MANAGER
26	SHALL OFFER TO PROVIDE:
27	(1) ITS CURRENT BEST ESTIMATE OF THE AMOUNT OF EACH ITEM;
28	AND
29	(2) AN UPDATED REPORT CONTAINING THE EXACT AMOUNT OF
30	EACH ITEM IMMEDIATELY AFTER IT BECOMES AVAILABLE.
. .	
31	(C) (1) A PHARMACY BENEFITS MANAGER SHALL PROVIDE THE
32	INFORMATION DESCRIBED IN SUBSECTIONS (A) AND (B) OF THIS SECTION IF
33	REQUESTED BY THE PURCHASER.

1(2)NOTWITHSTANDING THE PROVISIONS OF PARAGRAPH (1) OF2THIS SUBSECTION, IF A PHARMACY BENEFITS MANAGER REQUIRES A3NONDISCLOSURE AGREEMENT UNDER WHICH A PURCHASER AGREES THAT THE4INFORMATION IN SUBSECTIONS (A) AND (B) OF THIS SECTION IS PROPRIETARY5INFORMATION, THE PHARMACY BENEFITS MANAGER MAY NOT BE REQUIRED TO6PROVIDE THE INFORMATION UNTIL THE PURCHASER HAS SIGNED THE7NONDISCLOSURE AGREEMENT.

8 **<u>15–1605.</u>**

9 This subtitle does not diminish the authority of the Office of

10THE ATTORNEY GENERAL OR THE COMMISSIONER TO OBTAIN INFORMATION11RELATING TO A PHARMACY BENEFITS MANAGER AND USE THE INFORMATION IN

- 12 ANY PROCEEDING.
- 13 **<u>15–1606.</u>**

14(A) THE COMMISSIONER MAY ASSESS A CIVIL PENALTY NOT EXCEEDING15\$10,000 FOR EACH VIOLATION OF THIS SUBTITLE.

(B) IN ADDITION TO OR INSTEAD OF ASSESSING A CIVIL PENALTY, THE
 COMMISSIONER MAY REQUIRE THE PHARMACY BENEFITS MANAGER TO MAKE
 RESTITUTION TO ANY PERSON WHO HAS SUFFERED FINANCIAL INJURY BECAUSE
 OF THE VIOLATION OF THIS SUBTITLE.

20

Article – Health – General

21 19–706.

22(PPP)THE PROVISIONS OF TITLE 15, SUBTITLE 16 OF THE INSURANCE23ARTICLE APPLY TO HEALTH MAINTENANCE ORGANIZATIONS.

24 SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect 25 October 1, 2008.

Approved:

Governor.

Speaker of the House of Delegates.

President of the Senate.